期刊文献+

彩色多普勒超声评价乳腺癌新辅助化疗疗效的研究 被引量:8

Study of Color Doppler Ultrasonography in evaluating effcet of neoadjuvant chemotherapy to breast carcinoma
下载PDF
导出
摘要 目的:分析与新辅助化疗疗效相关的乳腺癌癌肿的声像图指标变化,与病理学检查结果进行比较,探讨彩色多普勒超声在乳腺癌新辅助化疗疗效评价上的应用价值。方法:利用彩色多普勒超声对接受新辅助化疗的43例乳腺癌患者的乳腺癌病灶变化进行观察,应用RECIST标准对乳腺癌新辅助化疗疗效进行评价,总结与新辅助化疗疗效相关的声像图指标。结果:本组43个病例通过临床触诊对新辅助化疗疗效进行评价,与病理学疗效评价符合率34.89%,敏感度59.09%;彩色多普勒超声检查评价乳腺癌病灶变化与病理学评价的符合率72.09%,敏感度86.36%,在病理判定有效组,新辅助化疗前后病灶内血流分级类型及RI值变化均具有显著性差异(P<0.05)。在病理判定无变化组,新辅助化疗前后病灶内血流分级类型及RI值变化均不具有显著性差异(P>0.05)。结论:彩色多普勒超声检查结合乳腺癌病灶的二维图像及血流信息,能对乳腺癌新辅助化疗后的疗效做出客观评价,具有一定的临床应用价值。 Objective:To study the relation of sonographical characters with the effect of neoadjuvant chemotherapy for breast cancer.Methods:All 43 patients with breast carcinoma were given CEF(CTX+EPI+5-FU).All the lesions were undergone CDFI.Results:According to the clinical palpation,the accuracy,sensitivity for palpation in evaluating effect of neoadjuvant chemotherapy were 34.89%,59.09%.According to the length of breast carcinoma lesion,the accuracy,sensitivity for US in evaluating effect of neoadjuvant chemotherapy were 72.09%,86.36%.In partial remission group,there were significant differences in the blood mode and RI value of the breast tumors between before and after chemotherapy(P0.05).In unchanged group,there was no difference in the blood mode and RI value of the breast tumors between before and after chemotherapy(P0.05).Conclusion:It was useful to appraise the effect of neoadjuvant chemotherapy to breast carcinoma by Color Doppler Ultrasonography.
出处 《现代肿瘤医学》 CAS 2011年第3期460-462,共3页 Journal of Modern Oncology
关键词 乳腺癌 彩色多普勒超声 新辅助化疗 breast carcinoma color Doppler flow imaging neoadjuvant chemotherapy
  • 相关文献

参考文献8

  • 1Smith IC, Hey SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel [ J]. J Clin Oncol,2002,20 : 1456.
  • 2Rajan R, Esteva FJ, Symmans WF. Pathologic changes in breast cancer following neoadjuvant chemotherapy implications for the assessment of response [ J ]. Clin Breast Cancer, 2004,5 ( 3 ) : 235 - 238.
  • 3Feldman L, Hortobagy G, Buzdar A, et al. Pathological assessment of response to induction chemotherapy in breast cancer[ J]. Cancer Res, 1986,46 (5) :2578 - 2581.
  • 4王殊,张嘉庆,乔新民,杨德启,佟富中.新辅助化疗后乳腺癌病理变化31例分析[J].中国妇产科临床杂志,2007,8(4):282-284. 被引量:7
  • 5Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging forrevealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy [ J ]. A JR,2002,179 (5) : 1193 - 1199.
  • 6Jos A, vander Hage, Comelis JH, et al. Preoperative chemotherapy in primary operable breast cancer: results from the european organization for research and treatment of caner trial [ J ]. J Clin Oneol, 2001,19:4224 - 4237.
  • 7Moon WK, Im JG, Noh DY, et al. Nonpalpable breast lesions: evaluation with power Doppler US and a microbubble contrast agentinitial experience[ J]. Radiology ,2000,217 ( 1 ) :240 - 246.
  • 8Lee SW, Choi HY, Baek SY, et al. Role of color and power doppler imaging in differentiating between malignant and benign solid breast masses[ J]. J Clin Ultrasound,2002,30(8 ) :459 -464.

二级参考文献8

  • 1[1]Mamounas EP,Fisher B.Preoperative (neoadjuvant) chemotherapy in patients with breast cancer.Semin Oncol,2001,28:389-399.
  • 2[2]van der Hage JA,van de Velde CJ,Julien JP,et al.Preoperative chemotherapy in primary operable breast cancer:results from the European Organization for Research and Treatment of Cancer trial 10902.J Clin Oncol,2001,19:4224 -4237.
  • 3[3]Wolmark N,Wang J,Mamounas E,et al.Preoperative chemotherapy in patients with operable breast cancer:nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.J Natl Cancer Inst Monogr,2001,30:96-102.
  • 4[4]Bonadonna G,Valagussa P,Brambilla C,et al.Primary chemotherapy in operable breast cancer:eight-year experience at the Milan Cancer Institute.J Clin Oncol,1998,16:93-100.
  • 5[5]Fisher B,Bryant J,Wolmark N,et al.Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol,1998,16:2672-2685.
  • 6[6]Kuerer HM,Sahin AA,Hunt KK,et al.Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvantchemotherapy.Ann Surg,1999,230:72-78.
  • 7[7]Lenert JT,Vlastos G,Mirza NQ,et al.Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients.Ann Surg Oncol,1999,6:762-767.
  • 8[8]Pierga JY,Mouret E,Laurence V,et al.Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer.the role of clinical response.Eur J Cancer,2003,39:1089-1096.

共引文献6

同被引文献79

引证文献8

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部